ÐÂÎÅÖÐÐÄ
News Center
ÖØ°õÊ×·¢ | CSCOÊײ¿¡¶Çý¶¯»ùÒòÒõÐÔ·ÇСϸ°û·Î°©¶þÏßÖÎÁÆÖйúר¼Ò¹²Ê¶¡·Ðû²¼, ÖйúÉúÎïÖÆÒ©°²ÂÞÌæÄáΪΨһ»ñÍÆ¿¹Ñª¹ÜÌìÉúÒ©Îï
Ðû²¼Ê±¼ä£º2024-03-04
·Î°©ÊÇÈ«Çò·¢²¡Âʵڶþ¡¢Öйú·¢²¡ÂʵÚÒ»µÄ¶ñÐÔÖ×Áö¡£¡£¡£ÆäÖзÇСϸ°û·Î°©(NSCLC)ÊǷΰ©µÄÖ÷Òª²¡ÀíÑÇÐÍ£¬£¬£¬Õ¼ËùÓв¡ÀýµÄ 85%-90%1¡£¡£¡£´ó´ó¶¼·Î°©»¼ÕßÊ×´ÎÕï¶ÏʱÒѾ´¦ÓÚÍíÆÚ¡£¡£¡£·Ö×Ó·ÖÐÍÖ¸µ¼Ïµľ«×¼ÖÎÁÆÏÔÖøÑÓÉìÁËNSCLC»¼ÕßµÄÉúÑÄʱ¼ä£¬£¬£¬È»¶ø£¬£¬£¬ÉÐÓÐÐí¶à»¼Õß²¢ÎÞÃ÷È·µÄÇý¶¯»ùÒòÍ»±ä¡£¡£¡£¹ØÓÚÇý¶¯»ùÒòÒõÐÔÍíÆÚNSCLC£¬£¬£¬ÃâÒß¼ì²éµãÒÖÖƼÁΪ»¼ÕßµÄÖÎÁÆ»ñÒæ´øÀ´ÁËÖØ´óÍ»ÆÆ£¬£¬£¬µ«´ó¶¼»¼ÕßÈÔÃæÁÙÄÍÒ©ÎÊÌâ¡£¡£¡£Ïֽ׶Σ¬£¬£¬¶ÔÃâÒß¾ÖÎÇý¶¯»ùÒòÒõÐÔNSCLC»¼ÕßµÄÁÙ´²Ñо¿Êý¾Ý½ÏΪØÑ·¦£¬£¬£¬µ±»¼Õß·ºÆð¼²²¡Ï£ÍûÐèÒª¶þÏßÖÎÁÆʱ£¬£¬£¬ÖÎÁÆÑ¡ÔñÒÀÈ»ÓÐÏÞ¡£¡£¡£
2024Äê2Ô£¬£¬£¬CSCOÊײ¿¡¶Çý¶¯»ùÒòÒõÐÔ·ÇСϸ°û·Î°©¶þÏßÖÎÁÆÖйúר¼Ò¹²Ê¶¡·£¨¼ò³Æ¡¶¹²Ê¶¡·£©ÕýʽÐû²¼£¬£¬£¬ÆäÖа²ÂÞÌæÄáÊÇΨһ»ñµÃ¹²Ê¶ÍƼöµÄ¿¹Ñª¹ÜÌìÉúÒ©Î·ÇÃâÒß¾Öλ¼Õß¼°ÃâÒßÁªºÏ»¯ÁƾÖλ¼Õ߶þÏßÖÎÁƵĶþ¼¶ÍƼö¡¢2AÀàÖ¤¾Ý£©2£¬£¬£¬Ìî²¹ÁËÇý¶¯»ùÒòÒõÐÔ¶þÏß°ÐÏòÖÎÁÆ¿Õȱ¡£¡£¡£
°²ÂÞÌæÄá×÷ΪһÀ࿹Ѫ¹ÜÌìÉú¶à°ÐµãС·Ö×ÓÀÒ°±ËἤøÒÖÖƼÁ£¨TKI£©£¬£¬£¬¿ÉÒÔ°ÐÏòѪ¹ÜÄÚƤÉú³¤Òò×ÓÊÜÌ壨VEGFR£©¡¢³ÉÏËάϸ°ûÉú³¤Òò×ÓÊÜÌ壨FGFR£©¡¢ÑªÐ¡°åÔ´ÐÔÉú³¤Òò×ÓÊÜÌ壨PDGFR£©ºÍc-kit£¬£¬£¬ÓÐÓÃÒÖÖÆÖ×ÁöѪ¹ÜÌìÉúºÍÖ×Áöϸ°ûÔöÖ³3¡£¡£¡£
.png "640(4)")
°²ÂÞÌæÄá×÷ÓûúÖÆ3
Ò»¡¢¹ØÓÚ·ÇÃâÒß¾Öλ¼ÕߵĶþÏßÖÎÁÆ£¬£¬£¬¡¶¹²Ê¶¡·ÍƼö¶àÎ÷ËûÈüÁªºÏ°²ÂÞÌæÄáÖÎÁÆ£¨2A£©£¬£¬£¬²»¿ÉÄÍÊÜ»¯ÁÆʱʹÓð²ÂÞÌæÄáÖÎÁÆ¡£¡£¡£
ALTER-L016Ñо¿4ÖУ¬£¬£¬57Àý»¼Õß½ÓÊÜ°²ÂÞÌæÄáÁªºÏ¶àÎ÷ËûÈüÖÎÁÆ£¬£¬£¬31Àý»¼Õß½ÓÊܶàÎ÷ËûÈüÖÎÁÆ¡£¡£¡£Ñо¿Ð§¹ûÏÔʾ£¬£¬£¬ÔÚÖÁÉÙ½ÓÊÜ1¸öÖÜÆÚÖÎÁƵĻ¼ÕßÖУ¬£¬£¬Ïà½ÏÓÚ¶àÎ÷ËûÈüµ¥Ò©£¬£¬£¬°²ÂÞÌæÄáÁªºÏ¶àÎ÷ËûÈüÏÔÖøÑÓÉìÁËÍíÆÚNSCLC »¼ÕßµÄÖÐλÎÞÏ£ÍûÉúÑÄÆÚ(mPFS) (5.4 vs 2.4¸öÔ£¬£¬£¬HR=0.41£¬£¬£¬95%CI: 0.24-0.71£¬£¬£¬P=0.001)£¬£¬£¬ ²¢ÇÒÌá¸ßÁ˿͹ۻº½âÂÊ(ORR) (30.4% vs 14.3%)ºÍ¼²²¡¿ØÖÆÂÊ(DCR) (96.4% vs 64.3%)¡£¡£¡£
ALTER-L018Ñо¿5Ò²ÏÔʾ³ö°²ÂÞÌæÄáÁªºÏ¶àÎ÷ËûÈüÓÃÓÚ±íƤÉú³¤Òò×ÓÊÜÌå(EGFR)Ò°ÉúÐÍÄÑÖÎÐÔÍíÆÚNSCLC»¼Õ߶þÏßÖÎÁÆ»ñÒ棬£¬£¬Óë¶àÎ÷ËûÈüµ¥Ò©Ïà±È£¬£¬£¬°²ÂÞÌæÄáÁªºÏ¶àÎ÷ËûÈüµÄmPFSÏÔÖøÑÓÉì (4.36 vs 1.64¸öÔ£¬£¬£¬HR=0.38£¬£¬£¬95%CI: 0.22-0.65£¬£¬£¬P<0.001)£¬£¬£¬²¢ÇÒ¿ÉÏÔÖøÌá¸ßORR(35.14% vs 9.52%£¬£¬£¬P=0.007)¼°DCR(83.78% vs 54.76%£¬£¬£¬P=0.006)¡£¡£¡£
¶þ¡¢¹ØÓÚÃâÒßÁªºÏ»¯ÁƾÖλ¼ÕߵĶþÏßÖÎÁÆ£¬£¬£¬¡¶¹²Ê¶¡·ÍƼö¶àÎ÷ËûÈüÁªºÏ°²ÂÞÌæÄá¾ÙÐÐÖÎÁÆ£¨2A£©£¬£¬£¬²»¿ÉÄÍÊÜ»¯ÁÆʱʹÓð²ÂÞÌæÄá¾ÙÐÐÖÎÁÆ¡£¡£¡£
ALTER-L016ÓëL018Ñо¿6¹²Èë×é73Àý¼ÈÍù½ÓÊܹýÃâÒß¼ì²éµãÒÖÖƼÁÖÎÁƵÄÖйúNSCLC»¼Õߣ¬£¬£¬ÆäÖжàÎ÷ËûÈüÁªºÏ°²ÂÞÌæÄá×é43Àý£¬£¬£¬¶àÎ÷ËûÈü×é30Àý¡£¡£¡£¶ÔÕⲿ·Ö»¼Õß¾ÙÐкϲ¢ÆÊÎöÏÔʾ£¬£¬£¬¶àÎ÷ËûÈüÁªºÏ°²ÂÞÌæÄá×éÓë¶àÎ÷ËûÈü×émPFS»®·ÖΪ7.60¸öÔºÍ2.50¸öÔ£¨HR=0.28£¬£¬£¬P<0.0001£©¡£¡£¡£
±ðµÄ£¬£¬£¬¹ØÓÚÇý¶¯»ùÒòÒõÐÔÍíÆÚNSCLC»¼ÕßµÄÈýÏß¼°ÒÔÉÏÖÎÁÆ£¬£¬£¬¹²Ê¶Ò²ÍƼöʹÓð²ÂÞÌæÄᣨһ¼¶ÍƼö£©¾ÙÐÐÖÎÁÆ¡£¡£¡£´ËÏîÍƼö»ùÓÚALTER 0303Ñо¿7µÄÊý¾ÝЧ¹û£¬£¬£¬Ñо¿ÄÉÈëÁË606Àý¾×é֯ѧ»òϸ°ûѧ֤ʵµÄNSCLC »¼Õߣ¬£¬£¬ÓÐÆÓªµÄÖÐÑëÐÍÁÛ״ϸ°û°©»òÄÔתÒÆÔîδ¿ØÖÆ»ò¿ØÖƲ»µ½2¸öÔµĻ¼Õß±»É¨³ý²¢ÒÔ2:1µÄ±ÈÀý±»Ëæ»ú·Ö×é¡£¡£¡£Ñо¿Ð§¹ûÏÔʾ£¬£¬£¬Óëο½å¼Á×éÏà±È£¬£¬£¬°²ÂÞÌæÄá×émOS (9.6 vs 6.3 ¸öÔ£¬£¬£¬HR=0.68£¬£¬£¬P=0.002)ºÍmPFS(5.4 vs 1.4 ¸öÔ£¬£¬£¬HR=0.25£¬£¬£¬P<0.001)¾ùÏÔÖøÑÓÉ죬£¬£¬ORRÏÔÖøÌá¸ß[27 (9.2%) vs 1 (0.7%), P<0.001]¡£¡£¡£Á½×éDCR¼ä²î±ðÒ²¾ßÓÐͳ¼ÆѧÒâÒå[238 (81.0%) vs 53 (37.1%), P<0.001]¡£¡£¡£
ÔÚÒÑÍù¼¸Ê®ÄêµÄÁÙ´²ÖУ¬£¬£¬Ô½À´Ô½¶àµÄÖ¤¾ÝÏÔʾÖ×ÁöÐÂÉúѪ¹ÜÔÚ¶àÖÖʵÌåÖ×ÁöµÄÉú³¤¡¢ÔöÖ³ºÍתÒÆÖÐÊ©Õ¹×ÅÖ÷Òª×÷Óᣡ£¡£Öî¶àÁÙ´²Êý¾ÝÒ²ÏÔʾ£¬£¬£¬¿¹Ñª¹ÜÌìÉúÒ©ÎïÓëÆäËûNSCLCϵͳÖÎÁÆÒ©ÎïÁªºÏʹÓÿÉÒÔ¸üÓÐÓõķ´¿¹Ö×Áö¡¢ÑÓ»ºÄÍÒ©£¬£¬£¬²¢ÇÒ²»Á¼·´Ó³¿É¿Ø¡£¡£¡£2018Äê5Ô£¬£¬£¬¿¹Ñª¹ÜÌìÉúÒ©Îï°²ÂÞÌæÄáÊ״λñ¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾ÖÅú×¼£¬£¬£¬ÓÃÓÚÍíÆÚNSCLCµÄÈýÏß¼°ÒÔÉÏÖÎÁÆ¡£¡£¡£Ê±¸ô6Ä꣬£¬£¬Ëæ×ÅÑо¿Êý¾ÝµÄÒ»Ö±³ÉÊ죬£¬£¬°²ÂÞÌæÄáÔÚÖÎÁÆÍíÆÚNSCLC·½Ãæ»ñµÃÁÙ´²µÄ½øÒ»²½ÈÏ¿É£¬£¬£¬¡¶Çý¶¯»ùÒòÒõÐÔ·ÇСϸ°û·Î°©¶þÏßÖÎÁÆÖйúר¼Ò¹²Ê¶¡·µÄÐû²¼£¬£¬£¬Ò²Èð²ÂÞÌæÄáµ¥Ò©»òÁªºÏ¶àÎ÷ËûÈü³ÉΪÇý¶¯»ùÒòÒõÐÔµÄÍíÆÚNSCLC¶þÏßÖÎÁÆбê×¼¡£¡£¡£Ëæ×ÅÁÙ´²Êý¾ÝµÄÓú¼ÓÏêʵ£¬£¬£¬Ò²±Ø½«ÎªÍíÆÚNSCLC»¼Õß´øÀ´¸ü¶à»ñÒæ¡£¡£¡£
²Î¿¼ÎÄÏ×£º
1. Bourreau C, Treps L, Faure S, et al. Therapeutic strategies for non- small cell lung cancer: Experimental models and emerging biomarkers to monitor drug efficacies. Pharmacol Ther, 2023, 242: 108347.
2. ÖйúÁÙ´²Ö×Áöѧ»á·ÇСϸ°û·Î°©×¨¼ÒίԱ»á. Çý¶¯»ùÒòÒõÐÔ·ÇСϸ°û·Î°©¶þÏßÖÎÁÆÖйúר¼Ò¹²Ê¶. Öйú·Î°©ÔÓÖ¾. 2024;27(2):81-87.
3. Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z, Zhao F, Ahmad R, Zhao J. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018 Sep 19;11(1):120.
4. Fang Y, Pan H, Shou J, et al. 1036P Anlotinib plus docetaxel vs. docetaxel as 2nd-line treatment of advanced non-small cell lung cancer (NSCLC): Updated results from ALTER-L016. Ann Oncol, 2022, 33(7 suppl): S1029.
5. Wu L, Wu Z, Xiao Z, et al. EP08.02-158 Final analyses of ALTER-L018: a randomized phase II trial of anlotinib plus docetaxel vs docetaxel as 2nd- line therapy for EGFR-negative NSCLC. J Thorac Oncol, 2022, 17(9): S480.
6£®Wu L, Fang Y. EP08.02-160 A pooled efficacy and safety analysis of anlotinib plus docetaxel in advanced NSCLC previously treated with immunotherapy. J Thorac Oncol, 2022, 17(9): S482-S483.
7. Han B, Li K, Wang Q , et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol, 2018, 4(11): 1569-1575.